Corcept Therapeutics: Rising Company in the Treatment of Cushing's Syndrome

Corcept Therapeutics is a specialist in cortisol modulation and controls the excess production of the stress hormone cortisol. Korlym treats Cushing's syndrome, a condition that is more widespread than previously thought, and drives strong revenue and profit growth. The long-term goal is to achieve revenue of $3 billion by 2029, driven by the new drug Relacorilant, which could expand the market reach beyond Korlym. Corcept Therapeutics (NASDAQ: CORT) specializes in developing drugs for the treatment of severe metabolic, cancer, and psychiatric...